X.T.L. Biopharmaceuticals EBIT

The latest EBIT for XTLB is $-2M as of December 2024. That compares with $260K in the prior-year period — down 877.6% year over year. That is below the Healthcare sector average of $22B. Investors often review this figure alongside X.T.L. Biopharmaceuticals's historical trend and sector peers before judging valuation or financial health.

Over the past year, XTLB's EBIT moved from $260K to $-2M — a 877.6% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in X.T.L. Biopharmaceuticals's operating scale or balance-sheet position.

Against Healthcare companies, XTLB currently prints $-2M for EBIT, while the sector average sits near $22B. That is roughly 100.0% below the sector mean. Large gaps often invite a closer look at X.T.L. Biopharmaceuticals's growth, margins, and balance sheet.

A EBIT figure of $-2M for XTLB is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The Healthcare average is about $22B. Explore the charts below for those layers of context.

After noting XTLB's EBIT ($-2M), review year-over-year change from $260K, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.